Theravance Biopharma Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Theravance Biopharma Inc.
Public Company Financings: Theravance sold its 85% interest in Trelegy royalties from GSK and Innoviva sold its 15% interest for up to $1.8bn in total. Also, ProKidney grossed $597m from its SPAC merger, Pliant raised $200m in a post-Phase IIa offering and Marinus earned $110m in a PRV sale.
Having recently bought antibacterial developer Entasis, Innoviva adds approved antibiotic Xerava and hypotension drug Giapreza to its portfolio along with La Jolla’s established commercial organization.
The US firm’s ampreloxetine flunked a second Phase III orthostatic hypotension study but positive data in a prespecified subset have left a narrow path for a potential collaboration and approval, its CEO tells Scrip.
While the stock prices of a few biotech companies have advanced significantly as a result of their pandemic efforts, a broad biotech stock index has underperformed the pharmaceutical index. Why?
- Drug Discovery Tools
- Other Names / Subsidiaries
- Theravance Biopharma Ireland Limited
- Theravance Biopharma US, Inc.